Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) Subsidiary's Product Eribulin Mesylate Injection Receives U.S. FDA Approval

Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that its subsidiary, Nanjing King-Friend Pharmaceutical Co., Ltd., recently received an ANDA approval notice from the U.S. Food and Drug Administration ("U.S. FDA") for Eribulin Mesylate Injection (1mg/2mL). The drug is indicated for patients with metastatic breast cancer who have previously received at least two chemotherapy regimens, and for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen. The newly approved product further enriches the company's international product pipeline and strengthens the company's international market presence.